Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN)

Historical Holders from Q1 2021 to Q3 2025

Symbol
TERN on Nasdaq
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
87,692,308
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
88,633,014
Holdings value
$665,699,966
% of all portfolios
0%
Number of holders
139
Number of buys
70
Number of sells
-55
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Soleus Capital Master Fund, L.P. 9.6% $23,776,100 8,142,500 Soleus Capital Master Fund, L.P. 31 Dec 2024
Deep Track Capital, LP 8.58% +36% $36,725,500 +$9,400,366 7,495,000 +34% Deep Track Capital, LP 30 Jun 2025
MORGAN STANLEY 8.1% $20,731,866 7,099,954 Morgan Stanley 31 Mar 2025
BlackRock, Inc. 6.8% $16,770,967 5,743,482 BlackRock, Inc. 31 Dec 2024
Commodore Capital LP 6.5% +24% $42,807,000 +$7,885,500 5,700,000 +23% Commodore Capital LP 30 Sep 2025
VANGUARD GROUP INC 5.21% $34,244,977 4,559,917 The Vanguard Group 30 Sep 2025
Schonfeld Strategic Advisors LLC 4.93% -20% $12,571,196 -$2,713,568 4,305,204 -18% Schonfeld Strategic Advisors LLC 31 Mar 2025
ORBIMED ADVISORS LLC 4.8% $31,842,911 4,240,068 ORBIMED ADVISORS LLC 03 Nov 2025
CITADEL ADVISORS LLC 4.1% $10,118,696 3,465,307 Kenneth Griffin 31 Dec 2024

Institutional Holders of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 88,633,014 $665,699,966 +$50,616,494 $7.51 139
2025 Q2 83,108,168 $309,995,477 +$2,354,788 $3.73 126
2025 Q1 83,089,113 $229,386,277 -$20,904,178 $2.76 134
2024 Q4 86,147,142 $477,240,000 +$3,828,882 $5.54 156
2024 Q3 79,491,087 $663,002,763 +$119,235,330 $8.34 153
2024 Q2 65,586,958 $446,681,549 +$17,184,836 $6.81 124
2024 Q1 63,239,404 $414,841,261 -$1,823,851 $6.56 112
2023 Q4 63,584,855 $412,672,679 +$14,024,936 $6.49 102
2023 Q3 61,708,912 $310,396,950 +$8,574,392 $5.03 92
2023 Q2 57,715,917 $505,015,397 +$31,653,493 $8.75 102
2023 Q1 53,226,532 $630,202,113 +$46,248,002 $11.84 79
2022 Q4 49,723,793 $506,193,882 +$199,453,477 $10.18 65
2022 Q3 30,203,299 $177,898,000 +$107,051,162 $5.89 43
2022 Q2 14,707,603 $36,472,000 -$6,462,439 $2.48 37
2022 Q1 16,836,162 $50,004,000 -$1,388,822 $2.97 43
2021 Q4 16,503,387 $116,663,000 -$4,531,477 $7.07 37
2021 Q3 16,724,968 $174,276,000 +$979,766 $10.42 33
2021 Q2 16,621,217 $203,777,000 -$24,794,385 $12.26 36
2021 Q1 17,905,204 $393,648,000 +$393,098,000 $22 41